August 12, 2016 07:00 AM EDT

Biotech venture champion Bill Maris is exiting GV. What’s next?

John Carroll

Editor & Founder

In the biotech startup world, GV (the venture group still usually referred to by its original name, Google Ventures) is the ideal investor. They bring …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Biotech venture champion Bill Maris is exiting GV. What’s next?

John Carroll

Editor & Founder

Sign up to read this article for free.

Trump taps Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, surgeon general picks

Incyte touts Monjuvi data from Phase 3 follicular lymphoma trial as it heads to FDA

Cassava shares plunge as controversial Alzheimer’s drug fails Phase 3 trial

Biohaven's myostatin inhibitor misses primary endpoint in spinal muscular atrophy trial

Gilead buys experimental HIV vaccines from a small Barcelona biotech

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Biotech ven­ture cham­pi­on Bill Maris is ex­it­ing GV. What’s next?

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

Trump taps Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, sur­geon gen­er­al picks

In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

Cas­sa­va shares plunge as con­tro­ver­sial Alzheimer’s drug fails Phase 3 tri­al

Bio­haven's myo­statin in­hibitor miss­es pri­ma­ry end­point in spinal mus­cu­lar at­ro­phy tri­al

Gilead buys ex­per­i­men­tal HIV vac­cines from a small Barcelona biotech

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Biotech venture champion Bill Maris is exiting GV. What’s next?

Trump taps Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, surgeon general picks

Incyte touts Monjuvi data from Phase 3 follicular lymphoma trial as it heads to FDA

Cassava shares plunge as controversial Alzheimer’s drug fails Phase 3 trial

Biohaven's myostatin inhibitor misses primary endpoint in spinal muscular atrophy trial

Gilead buys experimental HIV vaccines from a small Barcelona biotech

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam